Skip to content
Homepage
Author:
Pharvaris N.V.
Posted Date:
July 6, 2026
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Pharvaris N.V.
July 6, 2026
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Pharvaris N.V.
June 15, 2026
Pharvaris Announces Annual General Meeting of Shareholders
Pharvaris N.V.
June 11, 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris N.V.
May 29, 2026
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Pharvaris N.V.
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pharvaris N.V.
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pharvaris N.V.
May 12, 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Pharvaris N.V.
May 8, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris N.V.
April 20, 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Pharvaris N.V.
April 2, 2026
1
2
Next
